Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant TCH vs TCHL in HER2-positive breast cancer
2010-020966-34Phase 2Completed
- Sponsor
- Cancer Trials Ireland
- Start
- Jun 2010
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trastuzumab, docetaxel, carboplatin and lapatinib in breast cancer (2 arms), sponsored by Cancer Trials Ireland. Primary endpoint: Pathological complete response to TCH. Started Jun 2010; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2010-020966-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020966-34.